Developed by Shray Alag, The Harker School
Sections: Correlations,
Clinical Trials, and HPO
Navigate: Clinical Trials and HPO
Name (Synonyms) | Correlation | |
---|---|---|
drug391 | Baricitinib Wiki | 0.34 |
drug464 | Blood collection on their first consultation and 10 to 14 days later Wiki | 0.23 |
drug463 | Blood collection on admission and longitudinally Wiki | 0.23 |
Name (Synonyms) | Correlation | |
---|---|---|
drug466 | Blood draw Wiki | 0.19 |
drug469 | Blood for research purposes Wiki | 0.16 |
drug434 | Biological collection with nasopharyngeal samples, saliva, blood, stool and urine Wiki | 0.16 |
drug411 | Bereavement Virtual Support Group Wiki | 0.16 |
drug3763 | e-Psychotherapy Wiki | 0.16 |
drug3423 | Trauma-informed yoga video recording Wiki | 0.16 |
drug1951 | Meditation app usage Wiki | 0.16 |
drug167 | Aerobic Exercises Wiki | 0.16 |
drug2116 | Nasopharyngeal, oropharyngeal, or saliva swab Wiki | 0.16 |
drug385 | Background questionnaire Wiki | 0.16 |
drug3221 | Survey administration Wiki | 0.16 |
drug926 | Cross Sectional study using scientifically validated psychometric Scales Wiki | 0.16 |
drug256 | Anxiety Reduction Training Wiki | 0.16 |
drug451 | Biosensor Wiki | 0.16 |
drug2969 | Sarilumab 200 MG/1.14 ML Subcutaneous Solution [KEVZARA] Wiki | 0.16 |
drug898 | Coronavirus Anxiety Scale , COVID-19 Phobia Scale Wiki | 0.16 |
drug2631 | Prospective study across two time-points examining the impact of viral mitigation protocols on mental health Wiki | 0.16 |
drug1374 | HADS Wiki | 0.16 |
drug1213 | Experiences in Close Relationship Scale questionnaire (ECR-S) Wiki | 0.16 |
drug4038 | survey work Wiki | 0.16 |
drug1663 | Intervention App Wiki | 0.16 |
drug1235 | Eye Movement Desensitisation and Reprocessing Recent traumatic Event Protocol Wiki | 0.16 |
drug837 | Confinement and Communication During the COVID-19 Pandemic Wiki | 0.16 |
drug1739 | Kundalini Yoga and Anxiety Reduction Training Wiki | 0.16 |
drug1968 | Mental Health questionnaire Wiki | 0.16 |
drug3566 | Virtual-Care Cognitive Behavioural Therapy Wiki | 0.16 |
drug460 | Blood and derivatives. Wiki | 0.16 |
drug1934 | Maternal attachment, Edinburgh depression scoring and postpartum anxiety scale scores Wiki | 0.16 |
drug2378 | Patient Health Questionnaire (PHQ-9) Wiki | 0.16 |
drug928 | Cross-sectional study examining the impact of information sources to obtain information about COVID-19 on depression and anxiety symptoms Wiki | 0.16 |
drug457 | Blood D-dimer assay Wiki | 0.16 |
drug420 | Best available treatment Wiki | 0.16 |
drug452 | Biosensors Wiki | 0.16 |
drug785 | Cognitive Behavioural Group Therapy for Perinatal Anxiety Wiki | 0.16 |
drug410 | Berberine Wiki | 0.16 |
drug3658 | a survey Wiki | 0.16 |
drug835 | Computer task questionnaires Wiki | 0.16 |
drug461 | Blood collection Wiki | 0.16 |
drug429 | Biobehavioral Tele-rehabilitation Sessions Wiki | 0.16 |
drug440 | Biological test Wiki | 0.16 |
drug1601 | Impact of COVID-19 questionnaire Wiki | 0.16 |
drug3090 | Solution-Focused Support Program Wiki | 0.16 |
drug428 | Bioarginina® Wiki | 0.16 |
drug395 | Baricitinib or Anakinra Wiki | 0.16 |
drug446 | Biological: mRNA-1273: 100 mcg Wiki | 0.16 |
drug2641 | Psychoeducational intervention Wiki | 0.16 |
drug2559 | Post Traumatic Stress Disorder questionnaire (PTSD-8) Wiki | 0.16 |
drug2791 | Remote Problem Management Plus Wiki | 0.16 |
drug2970 | Sarilumab 400 MG/2.28 ML Subcutaneous Solution [KEVZARA] Wiki | 0.16 |
drug1187 | Essential Oil Blend Wiki | 0.16 |
drug1950 | Meditation and Anxiety Reduction Training Wiki | 0.16 |
drug770 | Clinical interview Wiki | 0.16 |
drug454 | Biospecimen collection Wiki | 0.16 |
drug2020 | MinnRAP Peer Support Program Wiki | 0.16 |
drug1273 | Feeling Good Digital App Wiki | 0.16 |
drug408 | Bemiparin sodium Wiki | 0.16 |
drug445 | Biological: COVID-19 convalescent plasma Wiki | 0.16 |
drug441 | Biological/Vaccine: Angiotensin peptide (1-7) derived plasma Wiki | 0.16 |
drug2363 | Pandemic control measures Wiki | 0.16 |
drug467 | Blood for anti-drug antibody (ADA) Wiki | 0.16 |
drug439 | Biological sampling Wiki | 0.16 |
drug851 | Control Blend Wiki | 0.16 |
drug1346 | Generalized Anxiety Disorder-7 (GAD 7) Wiki | 0.16 |
drug465 | Blood donation from convalescent donor Wiki | 0.16 |
drug2047 | Montmorrillonite Wiki | 0.16 |
drug2093 | NT-I7 Wiki | 0.16 |
drug431 | Biological Wiki | 0.16 |
drug3748 | covid-19 positive pregnant women Wiki | 0.16 |
drug462 | Blood collection at Day 8, Day 16, Day 24, Month 6 and Month 12 after first symptoms from SARS-CoV-2 infection Wiki | 0.16 |
drug447 | Biological: mRNA-1273: 50 mcg Wiki | 0.16 |
drug468 | Blood for pharmacokinetic samples Wiki | 0.16 |
drug406 | Behaviour Change Technique Intervention to Improve Quality of Life Wiki | 0.16 |
drug425 | Bicalutamide 150 Mg Oral Tablet Wiki | 0.11 |
drug407 | Bemiparin Wiki | 0.11 |
drug2274 | Online Questionnaire Wiki | 0.11 |
drug600 | COVID-19 RT-PCR Wiki | 0.09 |
drug2632 | Prospective study with two measurement points investigating the impact of viral mitigation protocols on mental health Wiki | 0.09 |
drug2751 | Ravulizumab Wiki | 0.09 |
drug2469 | Placebo Administration Wiki | 0.08 |
drug453 | Biospecimen Collection Wiki | 0.08 |
drug418 | Best Supportive Care Wiki | 0.08 |
drug2276 | Online Survey Wiki | 0.07 |
drug2951 | Saliva collection Wiki | 0.07 |
drug2782 | Remdesivir Wiki | 0.06 |
drug2687 | Questionnaire Administration Wiki | 0.05 |
drug1000 | Dexamethasone Wiki | 0.05 |
drug3218 | Survey Wiki | 0.04 |
drug2448 | Placebo Wiki | 0.04 |
drug3146 | Standard of care Wiki | 0.03 |
drug864 | Convalescent Plasma Wiki | 0.03 |
drug3138 | Standard of Care Wiki | 0.03 |
drug1472 | Hydroxychloroquine Wiki | 0.02 |
Name (Synonyms) | Correlation | |
---|---|---|
D003866 | Depressive Disorder NIH | 0.23 |
D003863 | Depression, NIH | 0.18 |
D019964 | Mood Disorders NIH | 0.16 |
Name (Synonyms) | Correlation | |
---|---|---|
D004194 | Disease NIH | 0.16 |
D040921 | Stress Disorders, Traumatic NIH | 0.13 |
D013313 | Stress Disorders, Post-Traumatic NIH | 0.12 |
D015775 | Fractures, Stress NIH | 0.11 |
D050497 | Stillbirth NIH | 0.11 |
D007752 | Obstetric Labor, Premature NIH | 0.11 |
D000068376 | Compassion Fatigue NIH | 0.11 |
D000067073 | Psychological Trauma NIH | 0.11 |
D013315 | Stress, Psychological NIH | 0.09 |
D001523 | Mental Disorders NIH | 0.07 |
D019052 | Depression, Postpartum NIH | 0.06 |
D000066553 | Problem Behavior NIH | 0.05 |
D020521 | Stroke NIH | 0.04 |
D000077062 | Burnout, Psychological NIH | 0.04 |
D016638 | Critical Illness NIH | 0.02 |
D045169 | Severe Acute Respiratory Syndrome NIH | 0.01 |
D018352 | Coronavirus Infections NIH | 0.01 |
Name (Synonyms) | Correlation | |
---|---|---|
HP:0000716 | Depressivity HPO | 0.23 |
HP:0003826 | Stillbirth HPO | 0.11 |
HP:0000708 | Behavioral abnormality HPO | 0.05 |
Name (Synonyms) | Correlation | |
---|---|---|
HP:0001297 | Stroke HPO | 0.04 |
Navigate: Correlations HPO
There are 38 clinical trials
The study aims to systematically examine various aspects of the anxiety associated with the COVID-19 pandemic in Germany. The data collection is carried out online with longitudinal repeated measurements.
Description: To investigate specific fears regarding the COVID-19 pandemic 9 self created items are used. Values ranging from 1 to 6, higher scores indicate a worse outcome.
Measure: Characteristics of COVID-19-related anxiety Time: 1 dayDescription: Modified German version of the DSM-5 Severity-Measure-For-Specific-Phobia-Adult-Scale by Beesdo-Baum et al. (2014). 10 items, values ranging from 1 to 5, higher scores indicate a worse outcome. The Scale was adapted to anxiety symptoms related to COVID-19.
Measure: COVID-19-related anxiety symptoms Time: 1 dayDescription: Self-efficacy and coping with the COVID-19 pandemic are measured with 13 self created items. Values ranging from 1 to 6; higher scores indicate a better outcome (except inverted items).
Measure: Self-efficacy and coping with COVID-19 Time: baseline (1 day) + after 3 weeks + after 6 weeks + after 9 weeks + after 6 months + after 12 monthsDescription: Personal consequences of the COVID-19 pandemic in the last three weeks are collected with five self-created items.
Measure: Consequences of COVID-19 in the last three weeks. Time: baseline (1 day) + after 3 weeks + after 6 weeks + after 9 weeks + after 6 months + after 12 monthsDescription: General illness attitudes are measured with 3 subscales (Worry about illness; Thanatophobia; Bodily preoccupations) of the German version of the Illness Attitude Scales (IAS) by Hiller & Rief (2004). 9 Items; values ranging from 1 to 5, higher scores indicate a worse outcome.
Measure: General Illness Attitude Time: baseline (1 day) + after 3 weeks + after 6 weeks + after 9 weeks + after 6 months + after 12 monthsDescription: Frequency, effects and formats of consumed media related to COVID-19 are measured with 5 self created items.
Measure: Media reporting Time: baseline (1 day) + after 3 weeks + after 6 weeks + after 9 weeks + after 6 months + after 12 monthsDescription: To screen for general anxiety and depressive symptoms the German version of the Patient Health Questionnaire-4 (PHQ-4) by Löwe (2015) is used. 4 items; values ranging from 0 to 3, higher scores indicate a worse outcome.
Measure: Ultra-brief screening scale for anxiety and depression Time: baseline (1 day) + after 3 weeks + after 6 weeks + after 9 weeks + after 6 months + after 12 monthsDescription: To investigate specific fears regarding the COVID-19 pandemic 9 self created items are used. Values ranging from 1 to 6, higher scores indicate a worse outcome.
Measure: Change in characteristics of COVID-19-related anxiety Time: Ebaseline (1 day) + after 3 weeks + after 6 weeks + after 9 weeks + after 6 months + after 12 monthsDescription: Modified German version of the DSM-5 Severity-Measure-For-Specific-Phobia-Adult-Scale by Beesdo-Baum et al. (2014). 10 items, values ranging from 1 to 5, higher scores indicate a worse outcome. The Scale was adapted to anxiety symptoms related to COVID-19.
Measure: Change in COVID-19-related anxiety symptoms Time: baseline (1 day) + after 3 weeks + after 6 weeks + after 9 weeks + after 6 months + after 12 monthsBackground: The COVID-19 outbreak has caused many changes to people s normal social patterns. The respiratory illness has been the major focus of public health efforts. But most experts also agree that government and public health mandates to slow the spread of the illness, such as social distancing, have a significant effect on people s mental health. Environmental stressors, such as constraints on activities, social contact, and access to resources, take a toll. Researchers want to learn how stressors related to COVID-19 affect mental health over time. Objective: To learn the relationship between stressors related to COVID-19 and self-rated measures of mental health symptoms and distress among a range of people. Eligibility: English-speaking adults ages 18 and older Design: This study will be conducted online. Participants will give their first and last name and email address. They will indicate if they have ever been in an NIH research study. They will get a username and password. Every 2 weeks for up to 6 months, participants will complete online study surveys. They will get email reminders. Some surveys will be repeated. At the end of the study, they will complete a set of end-of-study surveys. The surveys will ask about the following: Age, sex, race, and other sociodemographic data Mental and medical illness history and treatment Family medical history Mobility, self-care, and life activities Behaviors related to alcohol and substance use disorder Mental illness symptoms Psychological distress Stressors caused by the COVID-19 pandemic. Participants will get links to mental health resources, such as hotlines. They will also get guidance on steps to take to seek care or support. Study website: nimhcovidstudy.ctss.nih.gov
Description: Thoughts and feelings about mental health impact of COVID-19
Measure: NIMH COVID Study survey - adult responses Time: Biweekly online responsesDescription: Ratings on measures of mental health symptoms and distress
Measure: DSM XC and KS survey Time: Biweekly online self reportONCOVID is a prospective cohort study investigating oncology-patient-reported anxiety, mood, and quality of life during the COVID-19 pandemic. Participants complete a survey consisting of sociodemographic information and self-administered questionnaires (COVID-19 Peritraumatic Distress Index, Depression Anxiety Stress Scale-21, and WHO Quality of Life-BREF). Data collection occurs at baseline and follow-up surveys are performed after 6, 12, and 24 weeks.
Background: There is limited knowledge on the psychological implications of COVID-19 among hospitalized patients and their close relatives. Moreover, evidence-based psychological interventions targeting hospitalized COVID-19 patients and their relatives are currently lacking. Objective: To test a minimal psychoeducational intervention versus standard of care for reducing anxiety among hospitalized COVID-19 patients. Methods and analysis: The trial is a Randomized Controlled Trial (RCT) with a 1 month and 3 month follow-up. Hospitalized COVID-19 patients are consecutively included at admission and randomized 1:1 to either an intervention or control group. Patients randomized to the intervention group will receive a minimal psychoeducational intervention just prior to discharge from the hospital. The goal of the intervention is that patients will be prepared and learn to interpret and react to physical and psychological symptoms that are related to recovering from a COVID-19 infection. Data is collected using standardized and validated patient reported outcome measures (PROMs) to assess mental health outcomes. The primary outcome is patient reported anxiety as assess by the Hospital Anxiety and Depression Scale. Perspectives: This study will provide a comprehensive understanding of the psychological implications of the COVID-19 outbreak. If successful, the minimal intervention is easily implemented in daily clinical practice.
Description: Anxiety measured by the Hospital Anxiety and Depression Scale. Range in score: 0 - 28. Higher scores = more symptoms of anxiety.
Measure: Anxiety 1 month Time: 1 month post dischargeDescription: Anxiety measured by the Hospital Anxiety and Depression Scale. Range in score: 0 - 28. Higher scores = more symptoms of anxiety.
Measure: Anxiety 3 months Time: 3 months post dischargeDescription: Depression measured by the Hospital Anxiety and Depression Scale. Range in score: 0 - 28. Higher scores = more symptoms of depression.
Measure: Depression 3 months Time: 3 months post dischargeDescription: PTSD symptoms measured by the Harvard Trauma Questionnaire. Range in score: 16 - 64. Higher scores = more symptoms of PTSD
Measure: Post Traumatic Stress Disorder (PTSD) symptoms 3 months Time: 3 months post dischargeDescription: Anxiety measured by the Hospital Anxiety and Depression Scale. Range in score: 0 - 28. Higher scores = more symptoms of anxiety.
Measure: Anxiety 12 months Time: 12 months post dischargeDescription: PTSD symptoms measured by the Harvard Trauma Questionnaire. Range in score: 16 - 64. Higher scores = more symptoms of PTSD
Measure: Post Traumatic Stress Disorder (PTSD) symptoms 12 months Time: 12 months post dischargeDescription: Depression measured by the Hospital Anxiety and Depression Scale. Range in score: 0 - 28. Higher scores = more symptoms of depression.
Measure: Depression 12 months Time: 12 months post dischargeThis interventional study will investigate the effect of daily use of a mindfulness app on measures of participant anxiety, well-being, and future outlook during the Covid-19 pandemic, by comparing pre-intervention survey responses to post-intervention survey responses.
Description: Assessed by survey questions (in part adapted from GAD7)
Measure: Anxiety Time: Immediate post-intervention (compare with pre-intervention data)Description: Assessed by survey questions (in part adapted from WHO-5)
Measure: Well-being Time: Immediate post-intervention (compare with pre-intervention data)Description: Assessed by survey questions
Measure: Future outlook & hopefulness Time: Immediate post-intervention (compare with pre-intervention data)Description: Assessed by survey questions
Measure: Sleep habits Time: Immediate post-intervention (compare with pre-intervention data)Description: Assessed by survey questions (frequency of consuming whole foods and prepared meals)
Measure: Nutrition habits Time: Immediate post-intervention (compare with pre-intervention data)Description: Assessed by survey questions (anticipated and actual continued usage of app)
Measure: Meditation app continued usage Time: Immediate post-intervention (compare with pre-intervention data)Description: Assessed by survey questions (in part adapted from GAD7)
Measure: Anxiety Time: 2 months post-intervention (compare with pre-intervention, immediate post-intervention data)Description: Assessed by survey questions (in part adapted from WHO-5)
Measure: Well-being Time: 2 months post-intervention (compare with pre-intervention, immediate post-intervention data)Description: Assessed by survey questions
Measure: Future outlook & hopefulness Time: 2 months post-intervention (compare with pre-intervention, immediate post-intervention data)Description: Assessed by survey questions
Measure: Sleep habits Time: 2 months post-intervention (compare with pre-intervention, immediate post-intervention data)Description: Assessed by survey questions (frequency of consuming whole foods and prepared meals)
Measure: Nutrition habits Time: 2 months post-intervention (compare with pre-intervention, immediate post-intervention data)Description: Assessed by survey questions (anticipated and actual continued usage of app)
Measure: Meditation app continued usage Time: 2 months post-intervention (compare with immediate post-intervention data)This study seeks to investigate the levels of parental stress across different demographic subgroups in the general parental population during the strict social distancing government-initiated non-pharmacological interventions (NPI's) related to the COVID-19 pandemic. The study also seeks to examine the predictors of parental stress rates related to these non-pharmacological interventions (NPI's). In addition, the research will investigate the association between parental stress associated and psychopathology symptoms (i.e., depression and generalized anxiety). The aim of the project is to: - Inform the policymakers, the general public, scientists, and health practitioners about the psychological associations of the COVID-19-related government-initiated measures on parental stress, with special focus on the school and kindergarten lockdowns. - Provide a foundation for policymakers and health-care professionals to employ interventions that protect families against possibly increased psychological stressors. - Help policymakers and healthcare professionals to better understand the association of demographic variables and other predictors on parental stress and parent-child dysfunction, which information necessary for evaluating the psychological impact of NPIs on parental stress and thus the framework under which decisions about school/kindergarten lockdowns are made.
Description: Three items from the Danish Parental Stress Scale (PSS) was selected, which intends to be a short measure of perceived stress resulting from being a parent (Pontoppidan et al., 2018). The scale consists of nine items measuring parental stress where each is measured on a five-point Likert scale (1-5), with the scores ranging from 3 to 15. Higher scores indicate higher parental stress. The following three were chosen in this large-scale investigation: 1) I feel overwhelmed by the responsibility of being a parent. 2) The major source of stress in my life is my child(ren), and 3) It is difficult to balance different responsibilities because of my child(ren) (Pontoppidan et al., 2018).
Measure: Measure of parental stress Time: All data was collected between March 31st 2020 and April 7th 2020, a period where the NPIs (nonpharmacological interventions) against the COVID-19 pandemic were identical and constant in NorwayDescription: The Patient Health Questionnaire 9 (PHQ-9; Kroenke, Spitzer & Williams, 2001) is used to measure symptoms of depression in accordance with the diagnostic criteria for major depressive disorder. The questionnaire consists of nine items where each is scored on a four-point Likert scale (0-3), with the range of scores from 0 to 27. Higher scores indicate greater depression severity, and scores above 10 are considered as the cut-off that indicating that the patient is within the depressive area.
Measure: Patient Health Questionnaire 9 Time: All data was collected between March 31st 2020 and April 7th 2020, a period where the NPIs (nonpharmacological interventions) against the COVID-19 pandemic were identical and constant in NorwayDescription: The Generalized Anxiety Disorder 7 (GAD-7; Spitzer, Kroenke, Williams & Löwe, 2006) is a questionnaire consisting of seven items measuring symptoms of anxiety and worry. The items are scored on a four-point Likert scale (0-3), with the scores ranging from 0 to 21. Higher scores indicate greater anxiety severity, and scores that are above the cutoff of 10 are considered to be in the clinical range (Spitzer et al., 2006). Specific cut-off for Norwegian samples have been found yielding a cut-off of 8 and above for high sensitivity and specificity (Johnson, Ulvenes, Øktedalen & Hoffart, 2019).
Measure: Generalized Anxiety Disorder 7 Time: All data was collected between March 31st 2020 and April 7th 2020, a period where the NPIs (nonpharmacological interventions) against the COVID-19 pandemic were identical and constant in NorwayBackground: Researchers think that people s mental health and behavior will be very affected by the steps taken to slow the spread of COVID-19, such as social distancing. Also, the threat of disease and death, to people and their loved ones, can cause much stress. Researchers want to learn more about these stressors and how they are affecting people. Objective: To study the relationship of affective, cognitive, and behavioral responses to stressors related to COVID-19 with neuroimaging and behavioral data collected before COVID-19. Eligibility: English-speaking adults age 18 and older Design: This online study will include both new participants and those who have taken part in past National Institute of Mental Health studies. All will complete the same surveys and tasks. Participants will give their name and email address. They will get a username and password. The file that links their username to their personal data will be kept secure. Participants will complete a set of surveys about the following: - Sociodemographic data, such age, race, and income - Education and work status - Mental and medical illness and treatment - Family medical history - Mood - COVID-19 experience - Anxiety - Substance and alcohol use - Attention control - Other mental health related topics. Participants will complete a finger-tapping task. For this, they will press a key a certain number of times in a limited period. They will get to practice the task. After the task, they will complete a survey about it. It will take about 1 hour to complete the surveys and the task. About 8 months later, participants will be contacted to repeat the surveys and task. Compensation is provided.
Description: To examine patterns of neural circuits connectivity as potential predictors of rating scores of affective, cognitive and behavioral (including task performance) responses to COVID-19 among healthy and clinically anxious participants who already participants in SNFA resting-state connectivity studies.
Measure: Patterns of neural connectivity as predictors Time: Baseline and 14-20 months laterThe article presents a protocol of a cross-sectional study of mental health of pregnant women in relation to the COVID 19 pandemic. The primary aim is to compare differences in anxiety and depression scores of pregnant women between countries affected by the COVID-19 pandemic. The secondary aim is to assess demographic, economic, and social aspects affecting maternal anxiety and depression scores among pregnant women worldwide in the time of the COVID-19 pandemic. Finally, investigators will be able to compare differences in perception of the different aspects of the COVID-19 pandemic (social distancing, restrictions related to delivery) between countries and according to the epidemic status (number of infected patients, number of reported deaths). The comparisons will also be done according to COVID-19 status of the participants.
Description: Anxiety measured by General Anxiety Disorder-7 (GAD-7) scale. Scoring:5-9 mild; 10-14 moderate; >15 severe. Minimum 0, maximum 21 points
Measure: Anxiety Time: 4 monthsDescription: Depression measured by Patient Health Questionnaire-9 (PHQ-9) scale. Scoring: 5-9 mild;10-14 moderate; 15-19 moderately severe; >20 severe. Minimum 0 maximum 27 points
Measure: Depression Time: 4 monthsIn our study; Anxiety and depression levels, socio-demographic characteristics of the pregnant women who were admitted to our hospital between 25.04.2020-25.07.2020 and treated with the diagnosis of covid 19, and the change in anxiety and depression levelsWİTH Beck Depression and Anxiety Score after the disease regressed are planned. (Beck depression scale contains 10 questions and a total of 1 to 100 points is obtained. High score indicates that depression and anxiety are high.) 0-16 points = mild depressive symptoms 17-29 points = moderate depressive symptoms 30-63 points = severe depressive symptoms
Description: Evaluation of depression and anxiety score changes of covid-19 positive pregnants Pregnant women are questioned how this period was affected, as the pandemic period loaded with extra stress and caused depression and anxiety.
Measure: Evaluation of depression and anxiety score changes of covid-19 positive pregnants Time: 4 monthsThis randomized clinical on-line study examines whether whether a daily practice of meditation or Kundalini Yoga with anxiety reduction training leads to a greater reduction in anxiety than anxiety reduction training alone.
Description: Generalized Anxiety Disorder 7-item scale (range 0-21, higher is worse)
Measure: GAD-7 Time: Up to 32 weeksDescription: Health Anxiety 8-item scale (range 0-32, higher is worse)
Measure: Whiteley 8 Time: Up to 32 weeksDescription: Patient Health Questionnaire 8 - an 8 item measure of depression (range 0-24, higher is worse)
Measure: PHQ-8 Time: Up to 32 weeksDescription: Somatic Symptom Scale-8 an 8-item measure of symptom burden (range 0-32, higher is worse)
Measure: SS-8 Time: Up to 32 weeksDescription: An 8-item self-report measure of cognitive function (range 8-40, higher is worse)
Measure: Applied Cognition 1.0 Time: Up to 32 weeksDescription: A 4-item self-report assessment of sleep disturbance (range 4-20, higher is worse)
Measure: PROMIS-4 Sleep Disturbance Time: Up to 32 weeksDescription: Emotional Regulation Questionnaire - a 10-item measure of emotional regulation; the reappraisal subscale has a range: of 6-42, higher score is considered positive; while the suppression subscale has a range of 4-28, higher score considered negative. ..
Measure: ERQ Time: Up to 32 weeksDescription: A 10-item scale assessing the perception of events in one's life as stressful (0-40, higher represents higher perception of stress)
Measure: Perceived Stress Scale Time: Up to 32 weeksDescription: A 5-item scale assessing hypervigilance (0-20, higher represents greater hypervigilance)
Measure: Brief Hypervigilance Scale Time: Up to 32 weeksThis study aims at evaluating the effectiveness of a mobile phone based intervention to prevent and manage mental health problems in healthcare workers at the frontline against COVID-19 in Spain. The intervention will consist in psychoeducation, delivered via a mobile App. Participants will be followed up during two weeks. The primary outcome will be symptomatology of depression, anxiety or stress.
Description: Depression, anxiety and stress scales (DASS21). Score range: 0 (worst outcome) to 21 (best outcome)
Measure: Depression, anxiety and stress Time: 2 weeksDescription: Davidson Trauma Scale (DTS). The DTS is a 17-item, Likert-scale, self-report instrument that assesses the 17 DSM-IV symptoms of PTSD. Both a frequency and a severity score can be determined. The DTS yields a frequency score (ranging from 0 to 68), severity score (ranging from 0 to 68), and total score (ranging from 0 to 136). Higher scores are indicative a worse outcome.
Measure: Post-traumatic stress syndrome Time: 2 weeksDescription: Insomnia Severity Index. Score range: 0 (best outcome) to 28 (worst outcome)
Measure: Insomnia Time: 2 weeksDescription: General Self-Efficacy Scale. Score range: 10 (worst outcome) to 40 (best outcome)
Measure: Self Efficacy Time: 2 weeksThe Professional Peer Resilience Initiative (PPRI) study is an observational study aimed at understanding how symptoms of traumatic stress and resilience evolve over time in the University of Minnesota (UMN) healthcare workforce during the coronavirus disease 2019 (COVID-19) pandemic. The study is being conducted concurrently with a UMN peer support program called the MinnRAP program and will remotely administer quality of life and mental health surveys to healthcare workers before they start the MinnRAP program and throughout their participation in the program.
Description: Professional Quality of Life Questionnaire (proQOL): min score of 10; max score of 50; higher scores mean worse outcome
Measure: Change in professional quality of life Time: Before peer support program, through study completion (an average of 7 months)Description: Stress Risk & Resilience Self-Index: min score 0; max score of 12; higher scores mean worse outcome
Measure: Change in mental health symptoms and resilience markers Time: Before peer support program, through study completion (an average of 7 months)The effect and impact of postponing cardiac surgery / creating a waiting list as a result of COVID-19 on patients, both psychologically and symptomatically on three groups of patients: 1. The degree of anxiety and/or depression induced by their altered medical care trajectory. 2. The incidence of medical problems induced by deferred elective surgery or delayed postoperative ambulatory visit 3. The occurrence of reduced access to medical and psychological help
Description: The degree of anxiety and/or depression in all three groups, induced by their altered medical care trajectory. 0-7 = Normal 8-10 = Borderline abnormal (borderline case) 11-21 = Abnormal (case)
Measure: Anxiety/depression by means of Hospital Anxiety and Depression Scale (HADS) Time: 10 minutesDescription: The incidence of medical problems induced by deferred elective surgery or delayed postoperative ambulatory visit by means of an adjusted survey.
Measure: Medical problems induced by deferred elective surgery or delayed postoperative ambulatory visit Time: 10 minutesDescription: The occurrence of reduced access to medical and psychological help by means of an adjusted survey.
Measure: Reduced access to medical and psychological help Time: 10 minutesCoronavirus disease 2019 (COVID-19) and associated emergency measures (EM) have dramatically impacted the lives of children/adolescents (children) and families. The closure of schools, social and recreational activities, and modifications to work environments has led to significant changes in the way children and families are working, living and socializing. Although the impact on the mental health of children and families has not been well researched, it is anticipated that already stressed children and families with pre-COVID-19 mental health challenges are at significant risk for deterioration in their mental health. As such, the implementation, and evaluation (specifically: feasibility, acceptability and barriers) of virtual-care interventions to alleviate child and family anxiety and enhance family functioning are critical. Virtual-care also optimizes health equity initiatives in reducing social, economic and environmental barriers to services that can improve or maintain mental health (WHO, 2017; MOHLTC, 2018). The current study will evaluate an adapted virtual-care cognitive behavioural therapy (CBT) program for children with anxiety (VC-CBT). CBT has a strong evidence-base in treating children with anxiety disorders (Higa-McMillan, Francis, Rith-Najarian, and Chorpita, 2016; Seligman and Ollendick, 2011), with increasing evidence supporting the efficacy of virtual-care CBT for childhood anxiety disorders (Carpenter, Pincus, Furr, and Comer, 2018; Slone, Reese, and McClellan, 2012). This study aims to evaluate the feasibility, participation barriers related to social determinants of health (SDH) and acceptability of this virtual-care intervention in addressing mental health challenges associated with the COVID-19 pandemic and ensuing EM in the immediate time-period. Early evaluation of this virtual-care intervention will enable future scale-up of this intervention during the post-pandemic recovery time-period and during subsequent COVID-19 waves, if necessary.
Description: Participation barriers related to Social Determinants of Health (SDH) will be captured to assess intervention feasibility. Participation barriers will be captured using the Social Determinants of Health Questionnaire (unpublished).
Measure: Participation Barriers Time: The Social Determinants of Health Questionnaire will be administered at baseline only, for each participant (approximately one week prior to the first of twelve sessions in the intervention).Description: Number of participants that were eligible for the study.
Measure: Number of Eligible Participants Time: The number of participants that were eligible for the study will be captured through study completion, estimated at approximately 1 year.Description: Number of participants that were approached for the study.
Measure: Number of Participants Approached Time: The number of participants that were approached for the study will be captured through study completion, estimated at approximately 1 year.Description: Number of participants consented for the study.
Measure: Number of Participants Consented Time: The number of participants that were consented for the study will be captured through study completion, estimated at approximately 1 year.Description: Rates of refusal for participation in the study.
Measure: Rates of Refusal Time: The rates of refusal for participation in the study will be assessed through study completion, estimated at approximately 1 year.Description: Reasons for refusal for participation in the study.
Measure: Reasons for Refusal Time: The reasons of refusal for participation in the study will be assessed through study completion, estimated at approximately 1 year.Description: The average number of sessions completed in total will be captured to evaluate intervention adherence.
Measure: Number of Sessions Completed in Total Time: The average number of sessions completed in total, for each participant, will be assessed through study completion, estimated at approximately 1 year.Description: The adherence index (calculated using the formula: sessions completed/total sessions scheduled [sum of sessions attended, rescheduled, no-showed and cancelled]) will be used to evaluate intervention adherence.
Measure: Adherence Index Time: The adherence index, for each participant, will be assessed through study completion, estimated at approximately 1 year.Description: The amount of time (in weeks) to complete the intervention will be captured to evaluate intervention implementation experience.
Measure: Amount of time (in weeks) to complete the intervention Time: The amount of time (in weeks) to complete the intervention, for each participant, will be assessed through study completion, estimated at approximately 1 year.Description: The measure that will be used to assess the primary outcome of intervention acceptability is the Virtual Care Satisfaction Survey (Romanchych, unpublished).
Measure: Intervention Acceptability Time: The Virtual Care Satisfaction Survey will be administered once, within approximately one week after completion of the twelfth (final) intervention session (estimated to occur approximately 12 to 16 weeks after initiation of the study).Description: The measure that will be used to assess participant satisfaction is the Virtual Care Satisfaction Survey (Romanchych, unpublished).
Measure: Participant Satisfaction Time: The Virtual Care Satisfaction Survey will be administered once, within approximately one week after completion of the twelfth (final) intervention session (estimated to occur approximately 12 to 16 weeks after initiation of the study).Description: The Working Alliance Inventory will be used to assess participant satisfaction (WAI; Tracy & Kokotovic, 1989).
Measure: Working Alliance Inventory after First Intervention Session Time: The Working Alliance Inventory will be administered within approximately one week after completion of the first intervention session (estimated to occur approximately 1 to 2 weeks after initiation of the study).Description: The Working Alliance Inventory will be used to assess participant satisfaction (WAI; Tracy & Kokotovic, 1989).
Measure: Working Alliance Inventory after Sixth Intervention Session Time: The Working Alliance Inventory will be administered within approximately one week after completion of the sixth intervention session (estimated to occur approximately 6 to 8 weeks after initiation of the study).Description: The Working Alliance Inventory will be used to assess participant satisfaction (WAI; Tracy & Kokotovic, 1989).
Measure: Working Alliance Inventory after Final Intervention Session Time: The Working Alliance Inventory will be administered within approximately one week after completion of the twelfth (final) intervention session (estimated to occur approximately 12 to 16 weeks after initiation of the study).Description: Coronavirus disease 2019 (COVID-19) specific distress will be assessed using the CoRonavIruS Health Impact Survey (CRISIS; Merikangas et al., unpublished) V0.1 Parent/Caregiver or Youth Baseline Form. Many items from this scale address social determinants of health, which will allow for understanding of family social determinants of health at baseline and over the course of the virtual-care treatment.
Measure: Family Impact During a Pandemic at Baseline Time: CRISIS (parent/caregiver and youth forms) will be completed virtually by children and parents at baseline (approximately one week prior to the first of twelve sessions in the intervention).Description: Coronavirus disease 2019 (COVID-19) specific distress will be assessed using the CoRonavIruS Health Impact Survey (CRISIS; Merikangas et al., unpublished) V0.1 Parent/Caregiver or Youth Follow-Up Form. Many items from this scale address social determinants of health, which will allow for understanding of family social determinants of health at baseline and over the course of the virtual-care treatment.
Measure: Family Impact During a Pandemic after Final Intervention Session Time: CRISIS forms will be completed virtually by children and parents, within approximately one week of completion of the twelfth (final) intervention session (approximately 12 to 16 weeks after initiation of the study).Description: To evaluate the efficacy of the virtual-care CBT intervention, change in child anxiety will be measured using child and parent-report Screen for Child Anxiety Related Disorders (SCARED; Birmaher et al., 1997). The SCARED is a child and parent self-report instrument used to screen for childhood anxiety disorders including general anxiety disorder, separation anxiety disorder, panic disorder and social phobia. In addition, it assesses symptoms related to school phobia. A total score of 25 of higher on the SCARED measure may indicate the presence of an anxiety disorder. Scores higher than 30 are more specific.
Measure: Efficacy of Virtual-Care CBT Intervention Time: The SCARED questionnaire will be completed at both baseline and within approximately one week after completion of the twelfth (final) intervention session (estimated to occur approximately 12 to 16 weeks after study initiation).Description: In order to evaluate the experience of clinicians (at The Hospital for Sick Children (SickKids) and the Centre for Community Mental Health (CCMH)) using virtual-care platforms during the work from home shift due to COVID-19 and to identify any challenges they may be facing, a Clinician Virtual Care Experience Survey (Romanchych, unpublished) will be administered.
Measure: Clinician Virtual Care Experience Time: The Clinician Virtual Care Survey will be completed virtually by clinicians at both SickKids and CCMH at baseline.This study aims to identify the preference of the class modalities (classroom or online) in undergraduate and graduate students. Additionally, to explore if the presence of any mental state alterations such as depression or anxiety due to the COVID-19 pandemic can alter their perception of academic performance.
Description: This scale will explore the effort and confidence of the participants. The minimum score for each facet is 10, and the maximum score is 70.
Measure: Academic Self-Concept Scale Score Time: up to 3 monthsDescription: This inventory will be used to identify the presence and intensity of depressive disorders. The minimum score is 0, and the maximum score is 27.
Measure: PHQ-9 Score Time: up to 3 monthsDescription: This questionnaire will be used to evaluate the presence and intensity of anxiety disorders. The minimum score is 0, and the maximum score is 21.
Measure: GAD-7 Score Time: up to 3 monthsDescription: Students' preference of classroom or online classes.
Measure: Preference of teaching method Time: up to 3 monthsDescription: Students' perception of changes in their academic performance: got better, worse, or stayed the same.
Measure: Self perceived academic performance Time: up to 3 monthsDescription: Students' perception of changes in their grades: got better, worse, or stayed the same.
Measure: Academic grades changes Time: up to 3 monthsThe aim of the study is to explore the psychological effects of the COVID-19 pandemic among Hungarian adults with the use of an anonymous online questionnaire that consists of 65 items. With these results it will possible to identify coping strategies that can help Hungarian adults to deal with the difficulties arising from the pandemic.
Description: 6 items - age, sex, city of residence, marital status, level of education, employment status
Measure: sociodemopraphic factors Time: 5 monthsDescription: Perceived Stress Scale (PSS), 10 items about thoughts and feelings that characterize a person's perception of stress
Measure: perceived stress Time: 5 monthsDescription: The General Anxiety Disorder Assessment GAD-2, 2 items to examine the level of anxiety
Measure: level of anxiety Time: 5 monthsDescription: EQ5D-VAS, 1 item to examine health status
Measure: self-reported health state Time: 5 monthsDescription: Self-administered inventory of complaints (Hungarian questionnaire), 20 items to measure number of complaints.
Measure: number of complaints Time: 5 monthsDescription: Shortened (Hungarian) version of the Ways of Coping Questionnaire (WOC), 22 items to measure cognitive or behavioral strategies in coping with stressful situations
Measure: strategies in coping with stressful situations Time: 5 monthsDescription: psychological effects of the coronavirus pandemic on the participants' mood and ways of coping with difficulties arising from the pandemic, 2 open-ended questions (not obligatory to answer) in connection with psychological effects of the coronavirus pandemic (its effects on the participants' mood and ways of coping with difficulties arising from the pandemic).
Measure: psychological effects of the coronavirus pandemic on the participants' mood and ways of coping with difficulties arising from the pandemic Time: 5 monthsDescription: The Patient Health Questionnaire PHQ-2, 2 items to examine the level of depression
Measure: level of depression Time: 5 monthsStudy description: The present study seeks to investigate the predictors and maintaining mechanisms of depression and anxiety symptoms during the COVID-19 pandemic, exactly 3 months following the strictest viral mitigation strategies initiated in Norway in response to the pandemic. This is the time period where the major pandemic protocols are lifted in Norway, following three months of strict pandemic mitigation protocols. The study further aims to identify subgroups with highest levels of depressive and anxiety symptoms during the measurement period, to identify vulnerable subgroups with maintained symptoms three months following the pandemic. Hypotheses and research questions: Research Question 1: What is the level of depressive and anxiety symptoms three months following the employment of the strict viral mitigation protocols (i.e., physical distancing protocols) in the general adult population? What are the proportion above the validated cut-offs for depression and general anxiety? Hypothesis 1: There will be a significant decrease in the levels of depression and anxiety symptoms from the baseline (T1) with the strictest mitigation protocols to measurement the measurement period three months into pandemic (T2) where major pandemic mitigation protocols are lifted. Additionally, there will be a significant decrease in the proportion of the sample meeting validated cut-offs for depression and anxiety from T1 to T2. Hypothesis 2: Higher level at T1 and less reduction from T1 to T2 in positive metacognitions, negative metacognitions, and unhelpful coping strategies all measured with CAS-1, will be related to less reduction in depression and anxiety, above and beyond age, gender, and education. Higher level at T1 and increases from T1 to T2 in physical activity and perceived competence will be related to greater reduction in depression and anxiety, above and beyond, age, gender, and education. Exploratory: The investigators will further explore the proportion showing reliable change in depression and anxiety and investigate the differences in changes in depression and anxiety across different demographic subgroups in the sample
Description: • The Patient Health Questionnaire 9 (PHQ-9; Kroenke, Spitzer & Williams, 2001) is used to measure symptoms of depression in accordance with the diagnostic criteria for major depressive disorder. The questionnaire consists of nine items where each is scored on a four-point Likert scale (0-3), with the range of scores from 0 to 27. Higher scores indicate greater depression severity, and scores above 10 are considered as the cut-off that indicating that the patient is within the depressive area.
Measure: Patient Health Questionnaire 9 Time: Data is set to be collected starting from 22nd of June until enough data has been collected.The data collection period will last no longer than three weeks.Description: • The Generalized Anxiety Disorder 7 (GAD-7; Spitzer, Kroenke, Williams & Löwe, 2006) is a questionnaire consisting of seven items measuring symptoms of anxiety and worry. The items are scored on a four-point Likert scale (0-3), with the scores ranging from 0 to 21. Specific cut-off for Norwegian samples have been found yielding a cut-off of 8 and above for high sensitivity and specificity (Johnson, Ulvenes, Øktedalen & Hoffart, 2019).
Measure: Generalized Anxiety Disorder 7 Time: Data is set to be collected starting from 22nd of June until enough data has been collected.The data collection period will last no longer than three weeks.Study description: The present study seeks to investigate the impact of various sources of information on psychopathology, and specifically health anxiety, depression, and general anxiety, during the COVID-19 pandemic. The study will investigate the divergent impact of various information sources on these psychopathological symptoms during the pandemic. Hypotheses and research questions: Hypothesis 1: Media consumption across all information sources will significantly be associated with depression and anxiety symptoms, with increased media consumption in general associated with higher levels of health anxiety, depression, and general anxiety. Hypothesis 2: Using social media and online interactive platforms to obtain news about the pandemic in comparison to using traditional media (e.g., TV, radio, and newspapers) will be associated with higher levels of health anxiety, depression, and general anxiety. Actively staying away from information will further significantly be associated with higher levels of higher levels of health anxiety, depression, and general anxiety. Research Question 1: Is there a differential effect among different information sources on health anxiety, depression and general anxiety? To what extend and how are different information sources related to symptoms of health anxiety, depression, and general anxiety. Exploratory: Additionally, we will exploratory investigate to what extent the amount of use of different information sources impact health anxiety, depression, and general anxiety. We will also examine effect sizes with part correlations, to investigate information sources with the most and least detrimental impact on health anxiety, depression, and general anxiety. Furthermore, we will report which information platforms participants reported as most useful with regards to information concerning how to best deal with the pandemic.
Description: The Patient Health Questionnaire 9 (PHQ-9; Kroenke, Spitzer & Williams, 2001) is used to measure symptoms of depression in accordance with the diagnostic criteria for major depressive disorder. The questionnaire consists of nine items where each is scored on a four-point Likert scale (0-3), with the range of scores from 0 to 27. Higher scores indicate greater depression severity, and scores above 10 are considered as the cut-off that indicating that the patient is within the depressive area.
Measure: Patient Health Questionnaire 9 Time: Data is set to be collected starting from 22nd of June until enough data has been collected. The data collection period will last no longer than three weeks.Description: The Generalized Anxiety Disorder 7 (GAD-7; Spitzer, Kroenke, Williams & Löwe, 2006) is a questionnaire consisting of seven items measuring symptoms of anxiety and worry. The items are scored on a four-point Likert scale (0-3), with the scores ranging from 0 to 21. Specific cut-off for Norwegian samples have been found yielding a cut-off of 8 and above for high sensitivity and specificity (Johnson, Ulvenes, Øktedalen & Hoffart, 2019).
Measure: Generalized Anxiety Disorder 7 Time: Data is set to be collected starting from 22nd of June until enough data has been collected. The data collection period will last no longer than three weeks.This study aims to investigate the association between the use different information sources to obtain information about the COVID-19 pandemic and symptoms of psychopathology (i.e., depression and anxiety). Research Question: How central are different sources of information used to obtain knowledge about the COVID-19 pandemic in network along with depressive and anxiety symptoms? Which sources of information are most strongly connected to different symptoms of depression and anxiety? Staying away from information will be measured in the present study. As avoidance is a type of safety behavior in anxiety disorders, we are further eager to investigate the centrality of this behavior in the network. Furthermore, multiple studies using latent-variable paradigms have established a relationship between sum-scores of depression and social anxiety use in general. We are further interested in examining this potential link more thoroughly and detailed in the present network study. The findings of this study, although they will be cross-sectional and require further examination in studies with temporal data structure, will be an important and interesting starting point giving initial ideas about potential mechanisms that may be involved in use of information sources in pandemics and mental health
Description: The Patient Health Questionnaire 9 (PHQ-9; Kroenke, Spitzer & Williams, 2001) is used to measure symptoms of depression in accordance with the diagnostic criteria for major depressive disorder. The questionnaire consists of nine items where each is scored on a four-point Likert scale (0-3), with the range of scores from 0 to 27. Higher scores indicate greater depression severity, and scores above 10 are considered as the cut-off that indicating that the patient is within the depressive area.
Measure: The Patient Health Questionnaire 9 Time: Data is set to be collected starting from 22nd of June until enough data has been collected. The data collection period will last no longer than three weeks.Description: The Generalized Anxiety Disorder 7 (GAD-7; Spitzer, Kroenke, Williams & Löwe, 2006) is a questionnaire consisting of seven items measuring symptoms of anxiety and worry. The items are scored on a four-point Likert scale (0-3), with the scores ranging from 0 to 21. Specific cut-off for Norwegian samples have been found yielding a cut-off of 8 and above for high sensitivity and specificity (Johnson, Ulvenes, Øktedalen & Hoffart, 2019).
Measure: Generalized Anxiety Disorder 7 Time: Data is set to be collected starting from 22nd of June until enough data has been collected. The data collection period will last no longer than three weeks.Studies have shown that admission to hospital during a coronavirus epidemic is associated with increased levels of anxiety, depression and panic disorder. During the SARS-CoV-2 pandemic in North London the Royal Free Hospital admitted over 500 patients with Covid-19. As part of the standard of care, these patients are screened at 8 weeks post discharge for signs of anxiety and depression. The Feeling Good app is a NHS approved digital application which utilises applied relaxation, mindfulness based cognitive therapy and positive visualisation through audio tracks for the treatment of anxiety and depression. This is a naturalistic cohort study aimed to track the post illness psychological symptoms of those who have been admitted with Covid-19 to the Royal Free hospital up to 5-7 months after discharge. The study population is those who are exhibiting anxiety or depressive symptoms as measure by the PHQ-2 or TSQ questionnaires. All those with symptoms will be offered free access to a NHS approved app for anxiety and depression, and followed up for 3 months after recruitment to track changes to their symptoms.
Description: Generalised anxiety disorder score (GAD-7) scale. Score 0-21, with a higher score associated with greater anxiety symptoms. Scores of 5, 10, and 15 represent cut-points for mild, moderate, and severe anxiety, respectively. GAD-7 score at baseline will be controlled for.
Measure: Anxiety as measured by generalised anxiety disorder score (GAD-7) scale Time: Day 14Description: The Patient Health Questionnaire (PHQ-9) is a screening tool for the identification of depressive disorders, which has been validated for use in primary care. Each of the nine items in the questionnaire is based on the DSM diagnostic criteria for clinical depression. The PHQ-9 is scored out of 27 according to severity, where score of 5-9 indicates mild depression, 10-14 moderate, 15-19 moderately severe, and 20 or above severe depression.
Measure: Depression as measured by the patient health questionnaire 9 (PHQ-9) Time: 14 days and week 12Description: The Trauma screening questionnaire (TSQ) is a 10 point scale used to identify symptoms of post traumatic stress disorder (PTSD), with a score between 0 and 10, with a score of 6 or higher scored as positive.
Measure: Trauma as measured by Trauma screening questionnaire (TSQ) Time: 12 weeksDescription: Generalised anxiety disorder score (GAD-7) scale. Score 0-21, with a higher score associated with greater anxiety symptoms. Scores of 5, 10, and 15 represent cut-points for mild, moderate, and severe anxiety, respectively. GAD-7 score at baseline will be controlled for.
Measure: Anxiety as measured by generalised anxiety disorder score (GAD-7) scale Time: Week 12Description: Risk factors for psychological distress from admission with Covid-19 will be collected, these will include, age, gender, ethnicity, length of hospital stay, oxygen requirement, co-morbidites, years of education, smoking status, occupation.
Measure: Risk associated with distress Time: Baseline analysisDescription: Framework analysis. Qualitative feedback of patient experience. Semi structured interviews of a subset of patients will be performed to gain further insight into the patient experience. These will be analysed using a framework thematic analysis, to identify themes which will then be used to code the text.
Measure: Qualitative analysis Time: BaselineThis study will help the investigators understand whether it is feasible and acceptable for people to practice trauma-informed yoga using a pre-recorded video. This study will also explore the immediate effects of trauma-informed yoga on anxiety, mindfulness, and body awareness. The results of this study will inform future research on remote delivery of trauma-informed yoga for supporting psychological wellbeing.
Description: Total number of participants
Measure: Number of participants enrolled over 3 months Time: 3 monthsDescription: Count of participants enrolled each week
Measure: Number of participants enrolled per week over 3 months Time: 3 monthsDescription: Proportion of participants who enroll out of the total who access the consent form
Measure: Proportion of participants who enroll in the study over 3 months Time: 3 monthsDescription: Proportion of participants that reach the final page of the study out of the total who provided informed consent
Measure: Proportion of participants who complete the study over 3 months Time: 3 monthsDescription: Proportion of participants who filled out less than 70% of the items per questionnaire; mean proportion of items skipped per questionnaire
Measure: Proportion of missing data over 3 months Time: 3 monthsDescription: Proportion of participants who self-report watching the video in its entirety and for whom time stamps show that the time elapsed on the page where the video is embedded is greater than or equal to 80% of the length of the video
Measure: Proportion of participants who complete the 45-minute video over 3 months Time: 3 monthsDescription: The State Trait Anxiety Inventory (STAI) - Y6 is a 6-item, validated self-report questionnaire that assesses state anxiety when used with instructions that specify: "indicate how you feel right now, in this moment." Responses to each item are provided on a 4 point Likert Scale ('Not at all' to 'Very much'). The instrument is scored as the mean of 6 items, multiplied by 20 to use the interpretation guide for the full STAI scale.
Measure: Mean change in state anxiety from immediately before to immediately after yoga using the State Trait Anxiety Scale - 6 item short form Time: immediately before/afterDescription: The State Mindfulness Scale is a 21-item, validated self-report questionnaire that assesses state mindfulness. The State Mindfulness Scale is comprised of two subscales, State Mindfulness of Mind and State Mindfulness of Body. Responses to each item are provided on a 5 point Likert Scale ('Not at all' to 'Very much'). The instrument is scored as the sum of scores from each subscale. For this outcome, the State Mindfulness of Mind subscale will be used.
Measure: Mean change in state mindfulness from immediately before to immediately after yoga using the State Mindfulness Scale (State Mindfulness of Mind subscale) Time: immediately before/afterDescription: The State Mindfulness Scale is a 21-item, validated self-report questionnaire that assesses state mindfulness. The State Mindfulness Scale is comprised of two subscales, State Mindfulness of Mind and State Mindfulness of Body. Responses to each item are provided on a 5 point Likert Scale ('Not at all' to 'Very much'). The instrument is scored as the sum of scores from each subscale. For this outcome, the State Mindfulness of Body subscale will be used.
Measure: Mean change in body awareness from immediately before to immediately after yoga using the State Mindfulness Scale (State Mindfulness of Body subscale) Time: immediately before/afterIn this study, the investigator aims to measure stress, anxiety, mood, life satisfaction measures among elite athletes during COVID-19 and measure the relationship between these measures and the changes in training characteristics in elite athletes during the COVID-19 pandemic.
Description: Sociodemographic information and training characteristics Participants asked to provide sociodemographic information. Also, the difference in training frequency, duration, and quality after COVID-19 pandemic measured via 22 self-created questions.
Measure: Sociodemographic information and training characteristics Time: at inclusionDescription: The Beck Anxiety Inventory (Beck et al., 1988) has been widely used to measure the severity of anxiety by self-report and showed to has internal consistency and high test-retest reliability. The Turkish version of the BAI proved to be a reliable and valid measure (Ulusoy et al., 1993). The participant rates how much each symptom has bothered the participant in the past week in the 21-item self-report questionnaire. The symptoms are rated on a four-point scale, ranging from ''not at all'' (0) to ''severely'' (4).
Measure: The Beck Anxiety Inventory (BAI) Time: one weekDescription: The Visual Analogue Scale (0 not stressed at all - 10 maximum amount of stress) used to measure self-reported stress and anxiety in elite athletes before and during the COVID-19 pandemic. The VAS showed to be an efficient tool for assessing self-reported stress and anxiety.
Measure: The Visual Analogue Scale (VAS) Time: at inclusionDescription: The 14-item version of PSS scale asks patients how often they had experienced thoughts and feelings such as control irritations and stress during the previous one month, with responses ranging from 0 (never) to 4 (very often). The Turkish PSS proved to be a reliable and valid tool to measure perceived stress. The final score obtained by reversing responses (e.g., 0 = 4, 1 = 3, 2 = 2, 3 = 1 & 4 = 0) to the four positively stated items (items 4, 5, 7, & 8) and then summing across all scale items. Higher scores indicating higher levels of perceived stress.
Measure: Perceived Stress Scale (PSS) Time: one monthDescription: The Satisfaction with Life Scale (Diener, Emmons, Larsen, & Griffin, 1985) is a 5-item measure designed to measure global cognitive judgments of one's life satisfaction. The answers ranging from 1 (strongly disagree) to 7 (strongly agree). Items are summed to create a total score with higher scores indicating a greater degree of satisfaction with life.
Measure: Satisfaction with Life Scale Time: at inclusionDescription: The BRUMs scale is based on the Profile of Mood States. The Turkish version of the BRUMS scale studied on Turkish athletes, 24-item measures and six subscales in the original version decreased to 19 items and four subscales: anger, depression, vigor, fatigue. The results of the study proved to be valid and reliable (Cakiroglu et al., 2016). Each subscale has a numerical rating scale (0 = not at all, 1 = a bit, 2 = moderate, 3 = enough; 4 = extremely) from which research participant select the one best represents at that time. The results within the subscale are summed and a score range from 0 to 16.
Measure: Brunel mood scale (BRUMS) Time: at inclusionPrimary objective is to evaluate the feasibility of delivering an online early Eye Movement Desensitisation Reprocessing (EMDR) Recent Traumatic Events Protocol (R-TEP) to patients who have survived Covid-19 related critical illness, within the context of a randomised controlled trial (RCT). This will inform the design of a future RCT investigating the effectiveness of EMDR R-TEP in reducing psychological symptoms, for adult survivors of intensive care.
Description: Feasibility will be determined by the following measures: Able to recruit >30% of eligible patients approached Complete early EMDR intervention programme in 75% or more of trial participants randomised to intervention. Protocol adherence Assignment of causality of serious events will be assessed by the chief investigator. Events attributable to trial procedures will be reviewed by trial management board, study sponsor and the research ethics committee, in order to determine ongoing feasibility. Outcome measures completed in 75% or more of trial participants
Measure: Feasibility of recruitment, intervention adherence, incidence of treatment related adverse events and trial completion to final assessment timepoints Time: 12 monthsDescription: The PTSD Checklist-Civilian Version (PCL-C) is a validated, standardised self-reporting questionnaire for PTSD comprising of 17 items that correspond to key PTSD symptoms
Measure: Post-Traumatic stress disorder Time: 6 months post-hospital dischargeDescription: Hospital Anxiety and Depression Scale (HADS) is a 14-item, self-reported measure with 7-items relating to symptoms of anxiety and 7-items relating to depression
Measure: Anxiety and depression Time: 6 monthsDescription: Montreal Cognitive Assessment (MoCA) is a validated tool, used to detect cogntive impairment
Measure: Cognitive function Time: 6 months post-hospital dischargeDescription: EQ5D -5L comprises five quality-of-life dimensions; mobility, self-care, usual activities, pain/discomfort andanxiety/depression.
Measure: Health Related Quality of Life Time: 6 months post-hospital dischargeDescription: WHODAS 2.0 is a generic assessment tool that produces standarised disability levels and profiles
Measure: Health and disability Time: 6 months post-hospital dischargeDescription: Wrist worn physical activity monitoring
Measure: Physical activity Time: 6 months post-hospital dischargeDescription: Patient generated subjective global assessment
Measure: Nutritional status Time: 6 months post-hospital dischargeCovid-19, the infection caused by a novel corona virus detected in December 2019 in Wuhan (Hubei province), is now a pandemic announced by World Health Organization, raising concerns of widespread panic and increasing anxiety in individuals. This outbreak results in mass quarantine in Egypt since middle of March 2020. Brooks et al. (2019) reviewed and reported quarantine could bring "post traumatic stress symptoms, confusion, and anger. Stressors included longer quarantine duration, infection fears, frustration, boredom, inadequate supplies, inadequate information, financial loss, and stigma.". Many universities decided to suspend in-person classes and evacuate students in responding to the intensifying concerns surrounding Covid-19. This action can lead to negative psychological consequences among college students. Oral health related behavior and attitudes habits correlate with oral health status and can be considered to be its predictors . There is a claim of potential connection between high bacterial load in the mouth and complications associated with Covid-19 infection. Bacteria present in the meta genome of patients severely infected with Covid-19 included high reads for Prevotella, Staphylococcus, and Fusobacterium, all usually commensal organisms of the mouth. Over 80% of patients in ICU exhibited an exceptionally high bacterial load. Accordingly, the investigators assume that good oral hygiene better to be maintained during a Covid-19 outbreak in order to reduce the bacterial load in the mouth and the risk of a bacterial super infection in case of catching the infection . While there seems to be a common belief that psychosocial stress affects oral hygiene behavior, this assumption has rarely been proved9 Dental students, as the future providers of dental care, are ex¬pected to be role models for their patients regarding the oral hygiene practice and they supposed to be aware of the importance of preserving the oral health. Thus, we intended to select them as our population to study how the level of anxiety during pandemic could affect the practice of oral hygien
Description: By questionnaire
Measure: correlate between the level of anxiety and the practice of oral hygiene during covid-19 pandemic in dental students of Cairo university Time: 2 monthsThe recent COVID-19 pandemic has affected many aspects of individuals social life and its negative consequences on Canadian public health go far beyond the direct overload of the hospital care system. Self-isolation and financial uncertainty can significantly deteriorate individuals' mental health, which is only going to aggravate with prolonged physical distancing strategies. Adding to this is the personal and public trauma of lost lives and soon there will be an unprecedented epidemic of mental health problems with crushing effects on the public health sector and economy. To meet this huge new demand for an already strained health system, there is a need for innovative new approaches that significantly expand the capacity of care delivery. While it may not be possible in the short term to increase the number of mental healthcare providers or the number of hours they work, improving their time spent efficiently might be the solution. Virtual care and online delivery of psychotherapy, shown to be clinically effective, efficient and cost-effective, might be the perfect solution to address the high demand faced now. The investigators aim to establish the first academic online psychotherapy clinic to manage mental health problems secondary to COVID-19. The goal is to evaluate the feasibility and efficacy of treating COVID-19 related mental health issues in this clinic, offering a 10-week, diagnosis-specific, online psychotherapy program. The investigators will use the Online Psychotherapy Tool (OPTT), a secure cloud-based digital mental health platform, developed by the PI, Dr. Alavi. Potentially, this method of care delivery could increase care capacity by four-folds. The findings from this project have the potential to influence clinical practice and policy and increase accessibility to care during COVID-19 pandemic, without sacrificing the quality of care.
Description: The Depression, Anxiety and Stress Scale - 21 Items (DASS-21) - Scale: 0-3 (0 = never, 3 = frequently)
Measure: Change in Stress Time: Baseline, week 6, week 12Description: 14 Item Resilience Scale (RS-14) - Scale: 1-7 (1 = strongly disagree, 7 = strongly agree)
Measure: Change in Resilience Time: Baseline, week 6, week 12Description: The Quality of Life Enjoyment and Satisfaction Questionnaire (Q-LES-Q) - Scale: 1-5 (1 = very poor, 5 = very good)
Measure: Change in Quality of Life Assessment Time: Baseline, week 6, week 12Description: Generalized Anxiety Disorder 7 (GAD-7) - Scale: 0-3 (0 = not at all, 3 = nearly every day)
Measure: Change in Symptom Severity - 1 Time: Baseline, week 6, week 12Description: Montgomery-Asberg Depression Rating Scale (MADRS) - Scale: 0-6 (0 = not at all, 6 = frequent/very much)
Measure: Change in Symptom Severity - 2 Time: Baseline, week 6, week 12Description: Patient Health Questionnaire 9 (PHQ-9) - Scale: 0-3 (0 = not at all, 3 = nearly every day)
Measure: Change in Symptom Severity - 3 Time: Baseline, week 6, week 12Description: Healthcare providers who administered the e-psychotherapy for duration of project will be asked through focus groups questions surrounding the feasibility of providing the e-psychotherapy, how it compared to in-person psychotherapy with respect to time commitment, feelings of 'connectedness' to participant, and any perceived benefits/drawbacks to e-psychotherapy.
Measure: Qualitative Information: Healthcare Providers Time: Week 12Description: In focus groups, participants will be asked questions regarding personal, social, and cultural factors (gender, sexuality, background, supportive resources, structural/social barriers, etc.) that could impact participant experience with e-psychotherapy. This will be extracted using an Interpretive Phenomenological Analysis (IPA) approach.
Measure: Qualitative Information: Personal, social, and cultural factors Time: Week 12The coronavirus outbreak has adversely affected individuals in the community, as in the rest of the world. However, in order to carry out this epidemic period in a healthy and conscious manner, determining the anxiety levels of individuals in the society and supporting them psychologically is of great importance. In order to achieve this, healthcare professionals working clinically or academically have important duties. This study was planned to test its validity and reliability in order to adapt the Coronavirus Anxiety Scale to Turkish.
Description: anxiety increase in SARS-CoV-2 in humans.
Measure: Anxiety in SARS-CoV-2 Time: 4 weeksDescription: The ratio of SARS-CoV-2 anxiety scale to beck anxiety scale is similar.
Measure: Ratio of SARS-CoV-2 anxiety scale to beck anxiety scale Time: 4 weeksThe aim of this project is to evaluate the impact of pandemic and nonconfinement related to anxiety and eventual immune diseases with several standardized questionnaires : Implant Stability Quotient (ISQ) , Generalized Anxiety Disorder-7 (GAD-7), Patient Health Questionnaire -9 (PHQ-9), Post Traumatic Stress Disorder-8 (PTSD-8), and Experiences in Close Relationship Scale (ECRS).
Description: test that will evaluate persistent and excessive worry about a number of different things. People with Generalized Anxiety Disorder may anticipate disaster and may be overly concerned about money, health, family, work, or other issues. Individuals with Generalized Anxiety Disorder find it difficult to control their worry. Scored between 0-21: Cut offs: 0-4 = None 5-9 = Mild anxiety 10-14 = Moderate anxiety 15-21 = Severe anxiety
Measure: Results of the Generalized Anxiety Disorder (GAD-7) Time: 5 MinutesDescription: Welfare effect (mental health positively or negatively affected by COVID-19; why?) Scored between 7-42. These are treated as continuous variables.
Measure: Results of the Mental Health questionnaire Time: 5 minutesDescription: assess depression during the pandemic Scored between 0-27: Cut offs: 0-4 = None 5-9 = Mild depression 10-14 = Moderate depression 15-19 = Moderately severe depression 20-27 = Severe depression
Measure: Results of the Patient Health Questionnaire (PHQ-9) Time: 5 minutesDescription: Assessing the trauma of subjects during the pandemic Scored between 7-42. These are treated as continuous variables.
Measure: Results of the Post Traumatic Stress Disorder (PTSD-8) Time: 5 minutesDescription: Measuring social ties and attachment of subjects Scored between 7-42. These are treated as continuous variables.
Measure: Results of the Experiences in Close Relationship Scale questionnaire (ECR-S) Time: 5 minutesThis study will evaluate the effectiveness of an augmented version of our current evidence-based Cognitive Behavioural Group Therapy (CBGT) for perinatal anxiety protocol with cognitive and behavioural strategies composed of critical COVID-related anxiety, worry, and impact content.
Description: Changes in anxiety symptoms will be assessed through the STICSA to examine whether our augmented CBT for perinatal anxiety during a global pandemic is effective in reducing anxiety symptoms. Items on the STICSA are rated on a 4-point likert scale ranging from 1 (not at all) to 4 (very much so), with higher scores indicating worse anxiety symptoms. The STICSA has two subscales (i.e., cognitive subscale and somatic subscale) and a total score that will be used in analysis. Ten items comprise the cognitive subscale, meaning scores can range from 10-40. Eleven items comprise the somatic subscale, meaning scores can range from 11 -44. The total score is a sum of both subscales with possible total scores in the range of 21-84.
Measure: State-Trait Inventory of Cognitive and Somatic Anxiety (STICSA) Time: 8 weeksDescription: Due to the level of ongoing uncertainty that exists surrounding COVID-19, changes in intolerance of uncertainty will be assessed by the 27-item IUS to examine whether our augmented CBT for perinatal anxiety during a global pandemic is effective in reducing intolerance of uncertainty. The IUS can be scored across two-factors, in addition to a total score. Factor 1 includes items assessing uncertainty as having negative behavioural and self-referent implications (e.g., uncertainty keeps me from living a full life) and Factor 2 assesses uncertainty as being unfair and spoiling things in life (e.g., I can't stand being taken by surprise). Items are rated on a 5-point Likert type scale ranging from 1 (not at all characteristic of me) to 5 (entirely characteristic of me).
Measure: Intolerance of Uncertainty Scale (IUS) Time: 8 weeksDescription: Changes in worry symptoms will be assessed by the PSWQ. The PSWQ is a 16-item self-administered tool designed to assess worry symptoms. Items are assessed on a 5-point Likert scale ranging from 1 (not at all typical of me) to 5 (very typical of me), with higher scores indicating increased worry.
Measure: Penn State Worry Questionnaire (PSWQ) Time: 8 weeksDescription: Changes in mood symptoms will be assessed through the EPDS. Items on the EPDS are rated from 0-3, with higher total scores indicating more depressive symptoms. Possible scores on the EPDS range from 0-30. A clinical cut-off of 13 is used to indicate probable depression.
Measure: Edinburgh Postnatal Depression Scale (EPDS) Time: 8 weeksDescription: Changes in worry and anxiety associated with COVID-19 will be examined using the CSS. The CSS is a 36-item self-report scale designed to measure worry and anxiety associated with the novel COVID-19 pandemic. Each item is rated on a 5-point Likert scale ranging from 0 to 4. The CSS has 5 subscales: danger and contamination fears, fears about economic consequences, xenophobia, compulsive checking and traumatic stress symptoms.
Measure: COVID-19 Stress Scales (CSS) Time: 8 weeksDescription: Changes in pregnancy-specific anxiety will be assessed with the PRAQ-R2. Items are scored on 5-point Likert scale. Respondents are asked to circle the answer that applies most accurately to their situation and higher scores are reflective of greater pregnancy-specific anxiety. The PRAQ-R2 contains three subscales: fear of giving birth, worries about bearing a handicapped child, and concern about own appearance.
Measure: Pregnancy-Related Anxiety Questionnaire-Revised (PRAQ-R2) Time: 8 weeksDescription: Changes in postpartum-specific anxiety will be assessed with the PSAS. Items are scored on a 4-point Likert scale (0-3), with higher scores indicating greater anxiety symptoms. The PSAS has 4 subscales: maternal competence and attachment, infant safety and welfare, practical infant care, and psychosocial adjustment to motherhood.
Measure: Postpartum Specific Anxiety Scale (PSAS) Time: 8 weeksDescription: Changes in severity and impairment associated with anxiety will be assessed with the OASIS. Respondents are asked to circle that answer that best describes their experience over the past week and items are scored on a 5-point Likert scale.
Measure: Overall Anxiety Severity and Impairment Scale (OASIS) Time: 8 weeksDescription: Changes in parenting self-efficacy will be assessed with the PSOC. The PSOC is a 17-item self-report scale, in which items are scored on a 6-point Likert scale ranging from 1 (strongly disagree) to 6 (strongly agree), with higher scores reflecting greater parenting sense of competency.
Measure: Parenting Sense of Competence Scale (PSOC) Time: 8 weeksDescription: Changes in relationship satisfaction and adjustment will be assessed with the ADAS. The ADAS is a 7-item self-report scale, in which six of the items are scored on a 6-point Likert Scale, with higher scores reflecting greater relationship satisfaction. Item seven provides a global 'overall happiness' rating and is scored on 7-point Likert Scale ranging from 0 (extremely unhappy) to 6 (perfect).
Measure: Abbreviated Dyadic Adjustment Scale (ADAS) Time: 8 weeksDescription: Changes in perceived social support will be assessed with the SPS. Items are scored on a 4-point Likert scale ranging from 1 (strongly disagree) to 4 (strongly agree), with higher scores indicating higher levels of perceived social support. The SPS has 6 subscales assessing dimensions of attachment, social integration, reassurance of worth, guidance, nurturance and reliance.
Measure: Social Provisions Scale (SPS) Time: 8 weeksDescription: Changed in maternal attachment and bonding to the fetus will be assessed with the MAAS. For each item, respondents are asked to indicate the frequency in which each experience has occurred within the previous two weeks. The MAAS has two subscales that assess dimensions of quality of attachment and intensity of preoccupation. Items are scored on a 5-point Likert scale and scores range from 19 to 95 with higher scores indicating a higher level of attachment to the fetus.
Measure: Maternal Antenatal Attachment Scale (MAAS) Time: 8 weeksDescription: Changes in maternal bonding with the infant will be assessed with the PBQ. Items are scored on a 6-point Likert scale ranging from 0 (always) to 5 (never), with higher scores indicating lower levels of bonding with the infant. The PBQ has four subscales: general bonding, rejection and pathological anger, anxiety about the infant, and incipient abuse.
Measure: Postpartum Bonding Questionnaire (PBQ) Time: 8 weeksDescription: Client satisfaction of the augmented CBT for perinatal anxiety during a global pandemic will be assessed with the CSQ. Items are scored on a 4-point Likert scale from 1 to 4, with higher scores indicating higher levels of satisfaction with services.
Measure: Client Satisfaction Questionnaire (CSQ) Time: 8 weeksDescription: Changes in participants perceived level of stress will be assessed with the PSS. The PSS is a 14-item self-report scale, with items scored on a 5-point Likert scale from 0 to 4, with higher total scores indicating higher perceived stress.
Measure: Perceived Stress Scale (PSS) Time: 8 weeksThe purpose of this study is to assess the potential for a non-invasive sensory based intervention to reduce the stress associated with COVID-19 testing.
Description: The STAI-S is a validated self reporting instrument which assesses anxious feelings at that specific moment in time. Possible scores range from 20 to 60, with higher scores pointing to higher anxiety. The STAI-S contains 20 questions which are answered on a Likert scale.
Measure: Change from baseline in state anxiety on the State portion of the State Trait Anxiety Scale (STAI-S) at 15 minutes Time: Baseline and at 15 minutesPurpose: COVID-19 Pandemic has created fears, anxiety and worries among general population. COVID-19 airborne transmission is possible under circumstances in which procedures generate aerosols. Various dental treatment procedures can generate aerosols. This Cross Sectional Observational study was conducted with the following objectives: 1. Assessment of Fear of COVID-19 among netizens in Al Qassim province using FEAR OF COVID-19, a 5 item Likert Scale. 2. Assessment of Dental Anxiety among netizens in Al Qassim provincen using (MDA) Modified Dental Anxiety 5 item Likert Scale. Methods: Sample size was (n=385) estimated based on the population size in Al Qassim province (Confidence Interval 95%, Design effect 1 & hypothesized % frequency of outcome factor of 50%). Assessment of Fear of COVID-19 was estimated using FEAR OF COVID-19, a 5 item Likert Scale. Assessment of Dental Anxiety was estimated using Modified Dental Anxiety 5 item Likert Scale. An online Survey form (Arabic & English) was developed using Google form application. The Google form link was shared to the netizens of Al Qassim province, across Social media platforms. Statistical analysis is done using SPSS 22.00 software program.
Description: Assessed Fear of COVID-19 among netizens in Al Qassim province using FEAR OF COVID-19, a 5 item Likert Scale. Descriptive statistics is used to present the data.
Measure: Fear of COVID-19 infection Time: 5th August 2020Description: Assessed Dental Anxiety among netizens in Al Qassim province using (MDA) Modified Dental Anxiety 5 item Likert Scale. Descriptive statistics is used to present the data.
Measure: Dental Anxiety Time: 5th August 2020Description: The survey data is statistically analyzed to check for the correlation of the Fear of COVID-19 with Dental Anxiety among Netizens in Qassim region. The data obtained from the survey is subjected to appropriate analytical statistical tests to understand the correlation. A p-value of <0.05 is considered statistically significant correlation of the variables analysed.
Measure: Correlation of Fear of COVID-19 infection & Dental Anxiety Time: 5th August 2020Description: The survey data is statistically analyzed to check for the correlation of the nearest Dental treatment seeking time and Fear of COVID-19 infection. The data obtained from the survey is subjected to appropriate analytical statistical tests to understand the correlation. A p-value of <0.05 is considered statistically significant correlation of the variables analysed.
Measure: Correlation of the nearest Dental treatment seeking time and Fear of COVID-19 infection. Time: 5th August 2020Description: The survey data is statistically analyzed to check for the correlation of the nearest Dental treatment seeking time and Dental Anxiety. The data obtained from the survey is subjected to appropriate analytical statistical tests to understand the correlation. A p-value of <0.05 is considered statistically significant correlation of the variables analysed.
Measure: Correlation of the nearest Dental treatment seeking time and Dental Anxiety Time: 5th August 2020Description: The survey data is statistically analyzed to check for the correlation of Age and Fear of COVID-19 infection The data obtained from the survey is subjected to appropriate analytical statistical tests to understand the correlation. A p-value of <0.05 will be considered statistically significant correlation of the variables analysed.
Measure: Correlation of the Age and Fear of COVID-19 infection Time: 5th August 2020Description: The survey data is statistically analyzed to check for the correlation of the Age and Dental Anxiety. The data obtained from the survey is subjected to appropriate analytical statistical tests to understand the correlation. A p-value of <0.05 is considered statistically significant correlation of the variables analysed.
Measure: Correlation of the Age and Dental Anxiety. Time: 5th August 2020Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection has begun, first in Wuhan, China, and then became a pandemic. The first SARS-CoV-2 case in Turkey was reported on March 11, 2020. People older than 65 years old became subject to lock down measures beginning on March 21, while people younger than 20 years old became subject to lock down measures beginning on April 03. A total lock down has been implemented a few times lasting between 3 to 4 days, especially at weekends. Several studies show that mental health problems could occur in public during the SARS-CoV-2 pandemic. Depression and anxiety are a commonly known mental health issue in post-stroke patients. This patient population, who usually have to spend most of their time at home, remained completely at home and socially isolated due to the precautions required by the pandemic. Based on the above research evidence; depression, anxiety and phobia of SARS-CoV-2 may increase in the post stroke patients due to being in risk group and effects of measures taken against SARS-CoV-2 pandemic. Therefore, we aimed to assess the depression, anxiety and SARS-CoV-2 phobia in post stroke patients during SARS-CoV-2 outbreak, and to explore the potential influence factors.
Description: The Hospital Anxiety and Depression Scale evaluation includes a total of 14 questions (score range 0-3), which are scored to separately estimate anxiety and depressive status (7 questions each). The individual score for the anxiety and depression subscales may vary from 0 to 21. The aim of this scoring system is not to make an objective diagnosis, but to determine the current presence and tendency to anxiety or depression at the time of diagnosis. A HADS score of 8 to 10 is broadly accepted as indicating mild symptoms, a score between 11-16 suggests moderate anxiety or depression, and a score of 16 or more indicates severe anxiety or depressive symptoms
Measure: Hospital Anxiety and Depression Scale Time: 3 monthsDescription: The Covid 19 Phobia Scale is a self-report instrument with a five-point Likert-type scale to assess the levels of SARS-CoV-2 phobia. All items are rated on a 5-point scale from "strongly disagree (1)" to "strongly agree (5)." The scores on the scale can range between 20 and 100 and a higher score indicates a greater phobia in the respected subscales and total scale. In the present study total scale scores ranged from 20 to 100. The scale examines four main factors: psychological, psycho-somatic, economic and social
Measure: Covid 19 Phobia Scale Time: 3 monthsCapture of anxiety for anomalies, stillbirth and preterm Labor of pregnant women during COVID-19 pandemia
Description: Measurement of self-reported anxiety by a questionnaire and State-Trait Anxiety Inventory (STAI) and comparison with different empiric studies of anxiety for anomalies in pandemics
Measure: anxiety for anomalies during COVID-19-pandemic and before (percentage difference in agreement to the items of the questionnaire) Time: 6 monthsDescription: Measurement of self-reported anxiety by a questionnaire and State-Trait Anxiety Inventory (STAI) and comparison with different empiric studies of anxiety for stillbirths in pandemics
Measure: anxiety for stillbirths during COVID-19-pandemic and before (percentage difference in agreement to the items of the questionnaire) Time: 6 monthsDescription: Measurement of self-reported anxiety by a questionnaire and State-Trait Anxiety Inventory (STAI) and comparison with different empiric studies of anxiety for preterm labour in pandemics
Measure: anxiety for preterm labour during COVID-19-pandemic and before (percentage difference in agreement to the items of the questionnaire) Time: 6 monthsThe aim is to measure anxiety level and burnout frequency of healthcare workers including attending physicians, residents and nurses working at intensive care unit during COVID-19 pandemic. The study protocol had consisted of three parts. The first part was related to demographic details including age, sex, marital status, working position, past medical history. The second part of the survey was validated Turkish form of Beck anxiety inventory (BAI) It has 21 questions. Every question is a somatic symptom of anxiety. Participants scored them regarding how this symptom bothered them past week. Items have four possible answers: not at all (0 point), mildly (1 point), moderate (2 point), severe (3 point). Total anxiety score can be between 0 and 63. Participants were categorized as no or mild anxiety if the total beck anxiety score was between 0-16, and moderate to severe anxiety if it was more than 16 The last part of the survey was validated Turkish form of Maslach Burnout Inventory (MBI) to evaluate components of BOS
Description: Measured by Beck anxiety inventory. Total anxiety score can be between 0 and 63. Participants were categorized as no or mild anxiety if the total beck anxiety score was between 0-16, and moderate to severe anxiety if it was more than 16
Measure: Anxiety Time: 10-25 mayDescription: Measured by Maslach Burnout Inventory. MBI has 7-point 22 Likerd type questions and subdivided into three parts to measure emotional exhaustion (EE) (9 items), depersonalization (DP) (5 items), personal accomplishment (PA) (8 items). High scores on EE and DP subscales and low score on PA subscale imply higher level of burnout
Measure: Burnout Time: 10-25 mayIn this research, it was aimed to determine the anxiety levels of parents in the Covid-19 pandemic and to examine the effects of the Solution-Focused Support Program, which is planned to be given to parents with high anxiety levels.
Description: STAI was developed by Spielberg et al. In 1970 to measure the trait and state anxiety levels of individuals and was adapted to Turkish by Öner and Le Compte (1983) (Gilik and Avşaroğlu 2017). There are a total of 40 questions in the State-Trait Anxiety Scale. The State Anxiety Sub-Scale (STAI-S) evaluates how an individual feels at a particular time and under certain conditions. The Trait Anxiety Subscale (STAI-T) generally assesses how an individual feels. The scores obtained from both scales vary between 20 and 80. High score indicates high anxiety level, low score indicates low anxiety level.
Measure: State-Trait Anxiety Inventory (STAI) Time: 5 minutesThis is a pilot feasibility study of remotely delivered Problem Management Plus, a low-intensity psychological intervention, delivered in five sessions to adults affected by crisis. The current study will evaluate the feasibility and acceptability of the intervention when delivered remotely via Zoom to community members in New York City impacted by the COVID-19 pandemic. The investigator's goal is to use qualitative and quantitative approaches to inform procedures for a subsequent cluster randomized control trial of Problem Management Plus versus enhanced usual care. A mixed-methods design will be used to evaluate the feasibility, acceptability, perceived utility, and impact of the remotely delivered PM+ intervention, to determine recruitment and retention rates, to assess ethics and safety of trial procedures. Additionally, the study will evaluate the acceptability, feasibility and fidelity of the remote training and supervision of helpers trained to deliver the intervention.
Description: 4-item measure of personalized distress and client-generated problems, function and wellbeing; minimum value = 0, maximum value = 20; higher scores mean greater distress
Measure: Psychological Outcomes Profile; Unabbreviated scale title "Psychological Outcomes Profile" Time: 1 week post-interventionDescription: 9-item measure of depression symptoms; minimum value = 0, maximum value = 27; higher scores mean more severe depression symptoms
Measure: Patient Health Questionnaire; Unabbreviated scale title "Patient Health Questionnaire" Time: 1 week post-interventionDescription: 7-item measure of anxiety symptoms; minimum value = 0 and maximum value = 21; higher scores mean more severe anxiety symptoms
Measure: Generalized Anxiety Disorder Scale; Unabbreviated scale title "Generalized Anxiety Disorder 7-item Scale" Time: 1 week post-interventionDescription: 12-item measure of ability to engage in daily activities and functioning; minimum value = 0, maximum value = 48; higher scores mean worse disability outcomes
Measure: World Health Organization Disability Assessment Scale 2.0; Unabbreviated scale title "World Health Organization Disability Assessment Scale 2.0" Time: 1 week post-interventionDescription: 26-item quality of life assessment of physical health, psychological health, social, relationships and environment; minimum value = 26 and maximum value = 130; higher scores mean better quality of life
Measure: World Health Organization Quality of Life Questionnaire-BREF; Unabbreviated scale title "World Health Organization Quality of Life Questionnaire-BREF" Time: 1 week post-interventionDescription: 5-item assessment of dimensions of health status: mobility, self-care, usual activities, pain and discomfort, and anxiety and depression; minimum= 5, maximum = 25; higher score mean worse health outcomes
Measure: EuroQoL 5-dimension 5-level; Unabbreviated scale title "EuroQoL 5-dimension 5-level" Time: 1 week post-interventionDescription: 19-item measure of sleep quality and disturbance; 19 items combined to form 7 "component" scores, each of which has a range of 0-3 points, 7 component scores are added to yield one global global score; minimum value = 0 and maximum value = 21; higher score means greater difficulty sleeping
Measure: Pittsburgh Sleep Quality Index; Unabbreviated scale title "Pittsburgh Sleep Quality Index" Time: 1 week post-interventionDescription: 8-item assessment of the presence and severity of common somatic symptoms; minimum value = 0, maximum value = 32; higher score means more severe somatic symptoms
Measure: Somatic Symptom Scale-8; Unabbreviated scale title "Somatic Symptom Scale-8" Time: 1 week post-interventionMaternal attachment, Edinburgh depression scoring, and postpartum anxiety scale are evaluated in patients with covid-positive pregnancies in the 3rd month after birth.
Description: Maternal attachment scores evaluated in 250 covid-positive pregnant women in the 3rd month after birth. The results will be compared with the results of covid-negative pregnant women who gave birth in the same period. High scores from the scale indicate high maternal attachment.
Measure: Maternal attachment in SARS- cov2 positive and negative pregnant women Time: 3 monthsDescription: Edinburgh depression scores evaluated in 250 covid-positive pregnant women in the 3rd month after birth. The results will be compared with the results of covid-negative pregnant women who gave birth in the same period. All questions are scored between 0 and 3 and the highest possible score on the scale is 30. and shows advanced depression.
Measure: Edinburgh depression scores in in SARS- cov2 positive and negative pregnant women Time: 3 monthsDescription: Postpartum anxiety scale scores evaluated in 250 covid-positive pregnant women in the 3rd month after birth. The results will be compared with the results of covid-negative pregnant women who gave birth in the same period. It can be said that the postpartum anxiety levels of those who score 73 and below on the scale are low, those who score between 74 and 100 are medium, and those who score 101 and above are high.
Measure: Postpartum anxiety scale scores in in SARS- cov2 positive and negative pregnant women Time: 3 monthsA pandemic that originated in the Wuhan region of China in December 2019 was detected as a new type of coronavirus disease called coronavirus 2019 (COVID-19). In the first phase of the outbreak, specialists explained ways to maintain physical health . However, pediatric surgical procedures and anesthesia applications continued during this period. Surgery in pediatric patients is an unpleasant and potentially 'threatening' experience, often followed by preoperative anxiety due to the child's illness, hospitalization, fear of anesthesia - especially the time of anesthesia induction - and the surgery itself . Anesthesia is a stressful procedure for the child and the entire family. Both the COVID-19 pandemic and the surgical procedure are reflected in the symptoms of anxiety, fear or acute stress disorder for children and their families. As the disease spread, investigators started to emphasize the importance of protecting mental health. Identifying factors that contribute to significant preoperative anxiety levels in pediatric patients and their parents can help healthcare professionals choose the most appropriate from a variety of alternative strategies for anxiety control. This study was planned to evaluate the COVID-19 anxiety and phobia levels of the parents of pediatric patients are scheduled to undergo surgery under general anesthesia in Turkey.
Description: The Coronavirus Anxiety Scale (CAS), which was developed by Lee and validated in Turkish by Evren et al., was used to evaluate the COVID-19 anxiety level. In the validation study, the Cronbach's alpha of the Turkish version of CAS was 0.87. This results of the study showed that the CAS was highly reliable. CAS is a 5-point Likert-type scale. The scale consists of five questions and one dimension. Scoring of the scale is evaluated as 0 = never, 1 = rare, less than a day or two, 2 = a few days, 3 = more than a week, and 4 = almost every day in the last two weeks. The total score ranges from 0 to 20. Lee determined the CAS cut-off score of 9 to distinguish those with dysfunctional anxiety from those without anxiety.
Measure: Coronavirus Anxiety Scale (CAS) Time: 5 monthsDescription: COVID 19 phobia scale (C19P-S) is a 20-item, 4-subdimension (psychological, somatic, social and economic) scale in which items are answered in a 5-point response format developed by Arpacı et al. 7 to measure the phobia that may develop against COVID-19. In the validation study, the Cronbach's alpha of the Turkish version of C19P-S was 0.92. In the present study, Cronbach's alpha was 0.94. The results of the study demonstrated that the C19P-S was exceptionally reliable. The scale items are rated between 1 "strongly disagree" and 5, "strongly agree. Sub-dimension scores are obtained by the sum of the points of the answers given to the items belonging to that sub-dimension, while the total C19P-S score is obtained by the total of the subdimension scores, ranging between 20 and 100 points.
Measure: COVID 19 phobia scale (C19P-S) Time: 5 monthsAnxiety and depression disorders (ADD) have the highest overall prevalence rate among psychiatric disorders in young females. Its manifestations are disabling, distressing a substantial negative impact on the quality of life. The purpose of this study was to compare the effect of cognitive-behavioral therapy and physical therapy on female students with mild to moderate anxiety and depression.
Description: The DASS 21 is a 21 item self-report questionnaire designed to measure the severity of a range of symptoms common to both Depression and Anxiety
Measure: DASS 21 Time: 8 weeksAlphabetical listing of all HPO terms. Navigate: Correlations Clinical Trials
Data processed on December 13, 2020.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.
Drug Reports MeSH Reports HPO Reports